People · Operator
Named in public records as an officer, director or promoter · active 2014–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Graphite Bio, Inc. | — | Biotechnology | Series D+ | $150.7M | $4.9B | 2021 |
| Alliqua BioMedical, Inc. | — | Biotechnology | Series A | $52.6M | $100.1M | 2014 |
Perry Karsen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Perry Karsen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Johnson | 1 | 35 |
| Jerel Davis | 1 | 13 |
| Mark Wagner | 1 | 9 |
| James Sapirstein | 1 | 7 |
| Carlo Rizzuto | 1 | 7 |
| Steven Berger | 1 | 7 |
| Richard Rosenblum | 1 | 6 |
| Jerome Zeldis | 1 | 6 |
| Kenneth Londoner | 1 | 5 |
| Abraham Bassan | 1 | 4 |
| Joseph Sierchio | 1 | 3 |
| Brian Posner | 1 | 3 |
| Gary Restani | 1 | 3 |
| David Stefansky | 1 | 3 |
| Michael M. Goldberg | 1 | 2 |
| Josh Lehrer | 1 | 2 |
| Katherine Stultz | 1 | 2 |
| Matthew Porteus | 1 | 2 |
| Winston Kung | 1 | 1 |
| Steven C. Berger | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.